CMPX (Compass Therapeutics) Long-Term Debt: $0.00 Mil (As of Mar. 2026)


CMPX Compass Therapeutics Inc CMPX
23 GF Score
Price $2.34
! 2 Warning Signs
View Full Analysis

What is Compass Therapeutics Long-Term Debt?

Compass Therapeutics CMPX +0.86% 23 Long-Term Debt is $0.00 Mil as of Mar. 2026. GuruFocus rates CMPX with a GF Score™ of 23/100. The stock has 2 warning signs investors should review.

Compass Therapeutics's Long-Term Debt for the quarter that ended in Mar. 2026 was $0.00 Mil.

Compass Therapeutics  (NAS:CMPX) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Compass Therapeutics Long-Term Debt Related Terms

Compass Therapeutics Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Compass Therapeutics's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Compass Therapeutics Long-Term Debt Chart

Compass Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Compass Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
CMPX
23GF Score
Compass Therapeutics Inc CMPX
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of $0.00 Mil mean?
Compass Therapeutics (CMPX) has a Long-Term Debt of $0.00 Mil as of Mar. 2026.
Is Compass Therapeutics' Long-Term Debt too high?
Compass Therapeutics' current Long-Term Debt is $0.00 Mil. Overall, Compass Therapeutics has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Compass Therapeutics' Long-Term Debt compare to XFOR and LRMR?
Compass Therapeutics' Long-Term Debt of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Biotechnology company?
A good Long-Term Debt depends on the Biotechnology industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Compass Therapeutics's current Long-Term Debt is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Compass Therapeutics stock overvalued right now?
Compass Therapeutics (CMPX) has a current Long-Term Debt of $0.00 Mil. The current Long-Term Debt is $0.00 Mil. Compass Therapeutics' overall GF Score™ is 23/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Compass Therapeutics (CMPX), the current Long-Term Debt is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Compass Therapeutics Business Description

Address 80 Guest Street, Suite 601, Boston, MA, USA, 02135
Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.
23GF Score

Get the complete analysis for CMPX

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.34
Price